Research Article
Urinary 3-(3-Hydroxyphenyl)-3-hydroxypropionic Acid,
3-Hydroxyphenylacetic Acid, and 3-Hydroxyhippuric Acid Are
Elevated in Children with Autism Spectrum Disorders
Xiyue Xiong, Dan Liu, Yichao Wang, Ting Zeng, and Ying Peng
Maternal and Child Health Care Hospital of Hunan Province, Changsha 410008, China
CorrespondenceshouldbeaddressedtoYichaoWang;lisaoydwxy@126.com
Received19December2015;Accepted15March2016
AcademicEditor:JeroenVermeulen
Copyright Â© 2016 XiyueXiongetal. This is an open access article distributed under the Creative Commons Attribution License,
whichpermitsunrestricteduse,distribution,andreproductio ninanymedium,providedtheoriginalworkisproperlycited.
Autismspectrumdisorders(ASDs)areagroupofmentalillnesseshighlycorrelatedwithgutmicrobiota.Recentstudieshaveshown
that some abnormal aromatic metabolites in autism patients are presumably derived from overgrownClostridiumspecies in gut,
which may be used for diagnostic purposes. In this paper, a GC/MS based metabolomic approach was utilized to seek similar
biomarkers by analyzing the urinary information in 62 ASDs patients compared with 62 non-ASDs controls in China, aged 1.5â€“7.
Threecompoundsidentifiedas3-(3-hydroxyphenyl)-3-hydroxypropionicacid(HPHPA),3-hydroxyphenylaceticacid(3HPA),and
3-hydroxyhippuricacid(3HHA)werefoundinhigherconcentrationsinautisticchildrenthaninthecontrols( ğ‘<0.001).Afteroral
vancomycin treatment, urinaryexcretion of HPHPA (ğ‘<0.001), 3HPA (ğ‘<0.005), and 3HHA(ğ‘<0.001)decreasedmarkedly,
whichindicatedthatthesecompoundsmayalsobefromgut Clostridiumspecies.ThesensitivityandspecificityofHPHPA,3HPA,
and 3HHA were evaluated by receiver-operating characteristic (ROC) analysis. The specificity of each compound for ASDs was
veryhigh( >96%).Aftertwo-regressionanalysis,theoptimalareaunderthecurve(AUC,0.962),sensitivity(90.3%),andspecificity
(98.4%) were obtained by ROC curve of Prediction probability based on the three metabolites. These findings demonstrate that
themeasurementsofthethreecompoundsarestrongpredictorsofASDsandsupportthepotentialclinicalutilityforidentifyinga
subgroup of ASDs subjects.
1. Introduction
Autism spectrum disorders (ASDs) are neurodevelopmental
disorders characterized by limited social interaction, abnor-
mal use of language, and stereotypical behaviors, interests,
and activities [1]. During the last decades, ASDs prevalence
estimates have risen to as much as 113/10,000 children in
the USA (2012) and 62/10,000 globally [2], corresponding to
1:88 and 1:161 children, respectively. Hence this once rare
diseasehasnowbecomeoneofthemostfrequentconditions
i nc h i l dn e u r o p s y c h i a t r ya n di th a st ob ep a i dm o r ea t t e n -
tion to. ASDsâ€™s etiology and pathogenesis are not precisely
known, although genetic and environmental factors have
beenproposedasthetwoprimarycausesofASDsheritability
estimateshaveshownatrendofdecreaseinarecentstudy[3],
leaving sufficient room for environmental contributions to
explainASDs.
Amongenvironmentalfactorspossiblyrelevanttoclinical
feature, the overgrowth of unusual gut microbial species
in a sizable subgroup of autistic patients is of great inter-
est reported in several recent studies [4â€“8]. An excess of
RuminococcusandClostridiumspecies was initially reported
infecalsamplesfromASDspatientscomparedwiththecon-
trols [4]. Parracho found a higher incidence of theClostrid-
ium histolyticumgroup (Clostridiumclusters I and II) in the
fecal flora of 58 ASDs children compared to 10 healthy chil-
dren. Interestingly, 12 unaffected siblings of ASDs probands
displayed intermediate levels. Several members of theC.
histolyticumgroup are known toxin producers which could
leadtogutdysfunction[7].Adamsetal.foundlowerlevelsof
bifidobacteria in 58 ASDs children compared to 39 controls.
The growth of bifidobacteria may be inhibited by some
unusualmicrobialspeciesovergrowningut,suchas Clostrid-
iumspecies[8].Additionally,recentstudieshavedocumented
Hindawi Publishing Corporation
BioMed Research International
Volume 2016, Article ID 9485412, 8 pages
http://dx.doi.org/10.1155/2016/9485412
2 BioMedResearchInternational
elevated concentrations of abnormal aromatic metabolites
presumably derived from overgrownClostridiumspecies or
other gut microbiota in the urine of autistic individuals [9â€“
14].Inthisstudy,toseeksimilarmarkersandfurtherexplore
possible pathophysiologicalroles of gut microbiota in ASDs,
we have developed a GC-MS based metabolomic approach
forurineanalysisin62autisticindividualsandin62sex-and
age-matchednon-ASDscontrols.
2. Material and Methods
2.1.PatientRecruitmentandSampleCollection. Thisprospec-
tive study was approved by the Ethics Committee of Mater-
nity and Child Care Hospital of Hunan Province. Informed
consentwasobtainedfromtheparentsofthepatients.Sixty-
twopatients(48malesand14femalesagedfrom1.5to7years)
previously diagnosed with ASDs and age/gender-matched
non-ASDs controls (male 48, female 14) were obtained from
Maternity and Child Care Hospital of Hunan Province. All
the children with ASDs did not have a history of food
restricted. The controls were excluded with mental retarda-
tion, verbal disorder, attention deficit hyperactivity disorder,
and tics, and the ASDs cases were diagnosed according
to DSM-IV diagnostic criteria. Children included in the
study had no antianaerobic drug use history. Urine samples
were collected into untreated vials during routine medical
consultations,principallyinthemorning,andtheexacttime
of collection was recorded. Each urine sample was aliquoted
into1.5mLEppendorftubesandstoredat âˆ’70
âˆ˜Cimmediately
aftercollectionuntilanalysis.
2.2. Sample Pretreatment.The samples were pretreated as
described in our previous work [15]. Briefly, urine samples
werethawedatroomtemperatureandcentrifuged(at3000g)
for 10min and 100ğœ‡L urine samples (contained 2.5mmol/L
creatinine) was first treated with 30.0ğœ‡Lu r e a s e( 1 . 2U /ğœ‡L)
at 37
âˆ˜Cf o r3 0 m i nt or e m o v ei n t e r f e r i n gu r e aa n dt h e n
spiked with heptadecanoic acid (0.5mg/mL, 50ğœ‡L). Pro-
teins, including the added urease, were precipitated with
800ğœ‡L ethanol and removed after 15min centrifugation
(12000r/min). Forty microliters of 0.04mol/L hydroxy-
lamine hydrochloride and 60ğœ‡L of 0.05mol/L Ba(OH)
2was
addedtothedeproteinizedsolutionandthemixturewasthen
incubated at room temperature for 20min. Subsequently,
the mixture solution was evaporated to dryness, and the
compounds in the dried residue were converted to TMS
derivatives with 100ğœ‡Lo fB S T F A / T M C S( 1 0 0:1 )a n da n a -
lyzed by GC/MS. More experimental details can be found in
ourpatentedtechnology(ZL201210114246.2).
2.3. GC-MS Analysis. An Agilent GC-MS system (7890-
5975C)wasusedtoanalyzethederivativesamples.Asample
(1ğœ‡L) was injected with a split ratio of 50:1 into the GC
andthenseparatedwithafusedsilicaHP-5capillarycolumn
(30m, 0.25mm inside diameter, 0.25ğœ‡mt h i c k n e s so ft h e
innerliquidinthecolumn).Thechromatographicconditions
were as follows. The injector temperature was set at 250
âˆ˜C.
Highpuritynitrogenwasusedascarriergasataconstantflow
rateof1.5mL/min.Thecolumntemperaturewasinitiallykept
at 60âˆ˜Cf o r4m i n ,r a m p e dt o3 2 0âˆ˜Ca t6 . 5âˆ˜C/min, and then
heldfor10min.Theparametersofthemassspectrumwereas
follows.Theinterphasetemperatureandionsourcetempera-
turewere300
âˆ˜Cand230 âˆ˜C,respectively.Ionsweregenerated
byelectronicimpact(EI)at70eV.Masseswereacquiredfrom
ğ‘š/ğ‘§50 to 800. Drift of retention time of each peak was
minimized by locking heptadecanoic acid at 36.00min with
retention time locking technology (RTL, Agilent). GC/MSD
ChemStation Software was used for autoacquisition of GC
totalionchromatograms(TICs)andfragmentationpatterns.
Each compound had a fragmentation pattern composed of
as e r i e so fs p l i tm o l e c u l a ri o n s ;t h em a s sc h a r g er a t i o sa n d
theabundanceofwhichwerecomparedwithastandardmass
chromatogram in the NIST (National Institute of Standards
and Technology) mass spectra library by the ChemStation
Software. Peaks with similarity index more than 70% were
assignedcompoundnames.
The chromatograms were subjected to noise reduction,
and peaks with intensity higher than threefold of the ratio
of signal to noise (S/N) were recorded prior to peak area
integration. The relative intensity of each peak was normal-
ized against that of the internal standard in GC/MS run.
All known artifact peaks, such as peaks due to column
bleed and BSTFA artifact peaks, were not considered in
the final data analyses. Integrated peak areas of multiple
derivative peaks belonging to the same compound were
summedandconsideredasasinglecompound.Eachsample
wascharacterizedbythesamenumberofvariables,andeach
of these variables was represented across all observations
with the same sequence. Thus, a data matrix was generated
by intensities of the commensal peaks from all samples to
characterize the biochemical pattern of each sample. The
resultingthree-dimensionalmatrixconsistingofpeakindices
(retention time (RT)-ğ‘š/ğ‘§pairs), sample names (observa-
tions), and normalized peak areas (variables) was exported
forprincipalcomponentanalysis(PCA).
2.4. Statistical Analysis.After GC/MS analysis, each sample
was represented by a GC/MS TIC, and ion peak areas of
compounds were integrated. The peak area ratio of each
compound to creatinine was calculated as the response.
The results are expressed as ratios to the urinary creatinine
concentration. Statistical analysis was used for the compar-
ison of the metabolite levels to determine their significant
differences between the ASDs group and the control group.
The differentially expressed compounds with ğ‘values of
<0.05wereconsideredtobestatisticallysignificant.
Principal component analysis (PCA) was used to differ-
entiate the samples and performed by Mass Profiler Pro-
fessional software (Agilent). All of the data from the dif-
ferentially expressed compounds were used for constructing
PCA models. The score plots of the first three principal
components allowed the visualization of data and compar-
ison of samples between the ASDs and control group. The
classification performance (specificity and sensitivity) was
assessed by the area under the curve (AUC) of the receiver-
operatingcharacteristic(ROC)curves.
BioMedResearchInternational 3
Control
ASD
Ã—105
Ã—105
15 20 25 30 35 40 45 5010
Retention time (min)
15 20 25 30 35 40 45 5010
Retention time (min)
0
25
50
75
100
125
150
175
200Abundance
0
25
50
75
100
125
150Abundance
Figure 1: Representative GC/MS total ion chromatograms of the
samples from the control group and the ASDs group after chemical
derivatization.
3. Results and Discussion
3.1. Metabolomic Profiling of Urine Samples.Representative
GC/MSTICchromatogramsofurinesamplesfromtheASDs
group and the control group are displayed in Figure 1. The
majority of the peaks in the chromatograms were identi-
fied as endogenous metabolites by the NIST mass spectra
library, including amino acids, organic acids, carbohydrates,
amides,andfattyacids.TableS1inelectronicSupplementary
Material (see the Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9485412)showsthe96signals,
which could be autoidentified by the NIST library through
comparing their fragmentation patterns composed of all the
fragment ions. Peaks which could not be identified by the
NIST library are not listed. The first three fragment-ionğ‘š/ğ‘§
valueswiththehighestabundancewithineachfragmentation
pattern and the matching percentage to the NIST library are
listedinTableS1.
3.2. Pattern Recognition and Function Analysis.After nor-
malization of data using creatinine as internal standard, a
numberofdifferentiallyexpressedcompoundswith ğ‘values
of <0.05 were selected by statistical analysis to construct a
PCA model for assessment of the clustering of the ASDs
group and the control group. The PCA scores plot showed
a clear separation of the two groups besides only a few
ASDs cases (Figure 2(a)), which could be explained by the
fact that the etiology and pathogenesis of these cases are
probably caused by genetic factors. According to the pre-
viously reported studies, elevated concentration of 3-(3-
hydroxyphenyl)-3-hydroxypropionate (HPHPA) may be the
catabolism product of phenylalanine byClostridiumspecies
[9]. Interestingly, besides HPHPA, we also found two aro-
matic metabolites 3-hydroxyphenylacetic acid (3HPA) and
3-hydroxyhippuric acid (3HHA) among these differentially
expressed compounds. The three compounds were further
qualitatively analyzed by comparing their retention time
and fragment-ion of the chromatograms between the urine
sample and the corresponding standards (Figures S1â€“S4; see
SupplementaryMaterial).Allofthedatasupporttheidentifi-
cationofthethreecompoundsas3HPA,HPHPA,and3HHA,
respectively,Figures2(b),2(c),and2(d)graphicallyshowthe
concentration distribution of urinary HPHPA, 3HPA, and
3HHAbyage,respectively.Thegraphsclearlydistinguishthe
ASDscasesfromthecontrols.Thereisnocorrelationbetween
each pair of HPHPA, 3HHA, and 3HPA (ğ‘values were all
greater than 0.05, data not shown). Statistic results of the
threecompoundsweresummarizedinTable1.Therewereno
statisticaldifferencesinthemeansforage.3HPA( ğ‘<0.001),
HPHPA (ğ‘<0.001), and 3HHA (ğ‘<0.001) concentrations
were significantly higher in ASDs children compared with
age-matchedcontrols.
3.3. Effect of Vancomycin on Urinary Excretions of the Three
Compounds. Some studies tested vancomycin treatment for
ASDssincevancomycingivenorallyisvirtuallynotabsorbed,
anditisgenerallyeffectiveagainstgram-positivebacteriaand
Clostridia species [9, 16, 17]. For preventing the generation
of vancomycin resistance strains, we made some modifica-
tionsofvancomycintreatment.FiftyHPHPA-positiveautistic
children (9/50 patients 3HPA-positive and 17/50 patients
3HHA-positive)wereselectedfororalvancomycintreatment
at standard age-appropriate dosages (50mg/kg/d, 30 days
as one therapeutic course) followed by supplement therapy
with Bifidobacteriumagent (BifidobacteriumBB-12, 2 pills a
day).Afteronetherapeuticcourse,thetreatmentwasdiscon-
tinued for 15 days and the next course began only with
Bifidobacteriumagent treatment. The subsequentBifidobac-
terium agent treatment followed this cycle and continued
depending on the severity of patientsâ€™ condition assessed
by Autism Behavior Checklist (ABC) and the excretions
of the three compounds. Two months later, paired-sample
ğ‘¡- t e s tw a sa p p l i e dt ot e s tt h ec h a n g eo fa m o u n t so ft h e
three compounds before and after treatment. Significant
d e c r e a s e si nl e v e l so fH P H P A( m e a nv a l u ef r o m3 0 2 . 7 8t o
37.06mmol/mol creatinine,ğ‘<0.001 ), 3HPA (from 222.30
to 15.89mmol/mol creatinine,ğ‘<0.005), and 3HHA (from
56.59 to 5.95mmol/mol creatinine,ğ‘<0.001 )w e r ef o u n d
following the oral administration of vancomycin. HPHPA,
3HPA, and 3HHA were completely eliminated in 35/50, 6/9,
and12/17casesaftervancomycintreatment,respectively.Fol-
lowing the cessation of this treatment 3â€“6 months later, the
concentration of HPHPA almost recovered to its initial level
in 3 patients and recovered to 0.08â€“0.45 times their initial
valuesin12patients.Thelevelsof3HPAand3HHArecovered
to 0.1â€“0.3 times their initial values in 3 patients. This may
4 BioMedResearchInternational
âˆ’8
âˆ’6
âˆ’4
âˆ’2
0
2
4
6
8
Component 2 (5.79%)
501 0 1 5âˆ’5âˆ’10âˆ’15
Component 1 (25.5%)
(a)
1.0 2.0 3.0 4.0 5.0 6.0 7.0
Age (year)
ASD
Control
0
250
500
750
1000
1250HPHPA (mmol/mol creatinine)
(b)
1.0 2.0 3.0 4.0 5.0 6.0 7.0
Age (year)
0
100
200
300
400
500
6003HPA (mmol/mol creatinine)
ASD
Control
(c)
1.0 2.0 3.0 4.0 5.0 6.0 7.0
Age (year)
0
100
200
300
4003HHA (mmol/mol creatinine)
ASD
Control
(d)
Figure2:PCAscoresplotanddistributionsofthethreecompounds.(a)PCAscoresplotoftheASDsgroupfromthecontrolgroup.Triangles
represent the ASDs cases and squares represent the control cases. (b) Distribution of urinary HPHPA concentration by age between ASDs
andcontrolsubjects.(c)Distributionofurinary3HPAconcentrationbyagebetweenASDsandcontrolsubjects.(d)Distributionofurinary
3HHAconcentrationbyagebetweenASDsandcontrolsubjects.
beconsistentwiththefrequentrecurrenceofgastrointestinal
Clostridium species due to germination of resistant spores
following antibiotic treatment [9]. However, the recurrence
waslessseverecomparedwiththatinthesereportedstudies,
which may be attributed to the supplement therapy with
Bifidobacterium agent, a probiotic bacterium that benefits
the dynamic equilibrium for intestinal microecology. Fur-
thermore, after two therapeutic course treatments, the ABC
scoredecreasedsignificantly(meanvaluefrom73to59);90%
autistic children showed improved communication and eye
contact,butnoobviousimprovementinstereotypedbehavior
was seen. These findings indicated that these compounds
wereprobablyderivedfromovergrownintestinalmicrobiota,
andthepathogenesisofASDsmaybenotonlycorrelatedwith
overgrowngutpathogenicbacteria.
Additionally, the effect of this treatment on intestinal
symptoms was also studied. 32/62 children with ASDs have
frequent constipation; this gut symptom was positively cor-
related with the HPHPA level (Pearson correlation = 0.253,
ğ‘<0.05). In 50 HPHPA-positive patients employed for the
treatment, 22 individuals have constipation. Interestingly,
after two therapeutic course treatments, 22 patients with
constipationallshowedremarkableimprovementsinconsti-
pation, which revealed that gut symptoms in ASDs may also
resultedfromovergrowngutpathogenicbacteria.
3.4. Suggested Pathway for the Metabolism of HPHPA,
3HPA, and 3HHA.Based on preexisting hypothesis [9] and
our experimental results, we speculated that these com-
pounds were from disordered phenylalanine metabolism by
BioMedResearchInternational 5
T able1:Ar o ma ticmarkersfo undintheAS Dsgr o u pandtheco n tr olgr o u p .
Casestatus Measure Age(year) HPHPA
(mmol/molcreatinine)
3HPA
(mmol/molcreatinine)
3HHA
(mmol/molcreatinine)
Control(ğ‘›=62)
Frequency 15/62 1/62 4/62
Mean 3.45 15.53 0.61 1.12
Range 1.5â€“7.0 0â€“147.2 0â€“38.1 0â€“32.3
Std. dev. 1.62 31.56 4.82 4.89
ASDs(ğ‘›=62)
Frequency 50/62 18/62 21/62
Mean (ğ‘value) 3.69(0.407) 244.18(3.25Eâˆ’10) 57.99(1.48 Eâˆ’4) 31.02(6.34 Eâˆ’4)
Range 1.5â€“7.0 0â€“1282.4 0â€“543.2 0â€“370.2
Std. dev. 1.62 261.03 115.25 66.94
Table2:PredictivevaluesforASDsbasedonthethreecompounds.
Test Truepositive(sensitivity) Falsenegative(1 âˆ’sensitivity) Truenegative(specificity) Falsepositive(1 âˆ’specificity) Total
Criteria HPHPA >101.5mmol/molcreatinine
Control 61(98.4%) 1(1.6%) 62
ASDs 45(72.6%) 17(27.4%) 62
Criteria 3HPA >45.2mmol/molcreatinine
Control 62(100%) 0(0%) 62
ASDs 18(29%) 44(71%) 62
Criteria 3HHA >14.8mmol/molcreatinine
Control 60(96.8%) 2(3.2%) 62
ASDs 21(33.9%) 41(66.1%) 62
Criteria Prediction probability >0.65(basedonthethreemetabolites)
Control 98.4% 1.6%
ASDs 90.3% 9.7%
overgrown intestinal microbiota likeClostridiumspecies. As
shown in Figure 3, dietary phenylalanine firstly is converted
intom-tyrosine,o-tyrosine,and2,3-dihydroxyphenylalanine
by gut microbiota, for example, chloridazon-degrading bac-
teria [18]. It has been proved thatm-tyrosine induces a char-
acteristic behavioral syndrome in rats consisting of forepaw
padding, head weaving, backward walking, splayed hind
limbs,wetdogshakes,hyperactivity,andhyperreactivityand
depletes the brain of catecholamines. Therefore,m-tyrosine
might play a direct role in causing abnormal behaviors in
ASDs [19]. It is also possible thatm-tyrosine might form an
analogofdopamine,if m-tyrosineismetabolizedbythesame
enzymesthatconverttyrosinetodopamine(Figure3)[9].
m-Tyrosine converts to m-tyramine and 3-hydroxy-
phenylpropionic acid by decarboxylation and deamination,
respectively (Figure 3). It is documented thatEscherichia
coli could induce the activities of amine oxidase (MaoA)
and phenylacetaldehyde dehydrogenase (PadA) for the
catabolismofaromaticamines.Phenylethylamine,tyramine,
and dopamine are substrates of MaoA and PadA, leading
to formation of the corresponding aromatic acids, that
is, phenylacetic acid, 4-hydroxyphenylacetic acid, and 3,4-
dihydroxyphenylacetic acid, respectively [20, 21]. There-
f o r e ,3 H P Aw o u l db ee x p e c t e dt ob ef o r m e di ft h e r e
are amounts of m-tyramine for the substrate of the two
enzymes (Figure 3). Another metabolite fromm-tyrosine,
3-hydroxyphenylpropionic acid, converts into HPHPA and
3-hydroxybenzoic acid in order as reported by Shaw [9];
the latter product then conjugates with glycine and forms
3HHA(Figure3).
3.5. Sensitivity and Specificity.Receiver-operating character-
istic (ROC) analysis with sensitivity (true positives) and 1
minus specificity (false positives) of HPHPA, 3HPA, and
3HHA was used to evaluate the possibility of using these
markersfordiagnosingASDs.Selectedsensitivityandspeci-
ficity calculations for the three metabolites measures in
detectingASDscasesarepresentedinTable2.Highspecificity
(>9 6 % )w a so b t a i n e db ye a c hm e t a b o l i t ef o rA S D s .A ft e r
two-regressionanalysis,theoptimalAUC(0.962),sensitivity
(90.3%),andspecificity(98.4%)wereobtainedbyROCcurve
of Prediction probability based on the three metabolites
(Figure 4), which means that the three metabolites are good
discriminators to differentiate between ASDs and non-ASDs
control. These results indicate that the measurements of
the three metabolites are strong predictors of ASDs and
support the potential clinical utility for identifying a sub-
group of ASDs subjects in whom disordered phenylalanine
metabolismmaybeasalientcharacteristic.
4. Conclusions
The present metabolomic profile approach provides com-
prehensive analyses of metabolites in urine and elevated
levels of three aromatic acids HPHPA, 3HPA, and 3HHA
6 BioMedResearchInternational
OH
OH
OH OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
N
H
O
OH
Microbial
Microbial
Glycine
Phenylalanine
m-Tyrosine
3-Hydroxyphenylpropionic acid
3,5-Dihydroxyphenylalanine
(DOPA analog)
Dopamine analog
Norepinephrine analog
3-(3-Hydroxyphenyl)-3-hydroxypropionic acid
COOH
COOH
COOH
COOH
COOH
COOH
Beta-oxidation
Beta-oxidation
3-Hydroxyphenylacetic acid
3-Hydroxybenzoic acid
3-Hydroxyhippuric acid
Hydroxylase
Decarboxylase
m-Tyramine
Microbial
Microbial
Microbial
Microbial
2,3-Dihydroxyphenylalanine
COOH COOH
COOH COOH
OH
o-Tyrosine
MaoA
PadA
HO
HO
HO
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
Figure3:SuggestedpathwayforthemetabolismofHPHPA,3HPA,and3HHA.
were found in ASDs group compared with the controls. In
particular, vancomycin has significant effect on decreasing
theexcretionsofthesecompounds,whichindicatedthatthey
seemed to be derived from intestinal microbiota. Further
studies will have to define the degree of overlap between
elevated urinary HPHPA, 3HPA, and 3HHA and intestinal
microbiota composition in ASDs patients, as well as their
potentialrelationshipwithgastrointestinalsymptoms,abnor-
malbeha vior ,andpersonalizedr esponsetopharmacological
treatments. Additionally, the sensitivity and specificity data
assessedbyROCanalysisdemonstratethatthemeasurements
ofthethreemetabolitesarestrongindicatorsofASDs.
Abbreviations
ASDs: Autismspectrumdisorders
ABC: AutismBehaviorChecklist
AUC: Areaunderthecurve
BSTFA: Bis(trimethylsilyl)trifluoroacetamide
TMCS: Trimethylchlorosilane
BioMedResearchInternational 7
AUC = 0.962
0.2 0.4 0.6 0.8 1.00.0
False positive (1âˆ’ specificity)
0.0
0.2
0.4
0.6
0.8
1.0True positive (sensitivity)
Figure4:ROCcurveperformedbythePredictionprobabilitybased
onthethreemetabolites.AUCvaluewas0.962.
DSM: Diagnostic and Statistical Manual of Mental
Disorders
GC/MS: Gaschromatography-massspectrometry
HPHPA: 3-(3-Hydroxyphenyl)-3-hydroxypropionicacid
3HPA: 3-Hydroxyphenylaceticacid
3HHA: 3-Hydroxyhippuricacid
NIST: NationalInstituteofStandardsandTechnology
PCA: Principalcomponentanalysis
ROC: Receiver-operatingcharacteristic.
Competing Interests
Theauthorsdeclarethattheyhavenocompetinginterests.
Authorsâ€™ Contributions
Yichao Wang provided a mentoring and supervisory role
throughout this project. Xiyue Xiong and Dan Liu con-
tributedequallytothework;theyperformedtheexperiments,
analyzed the data, and prepared the paper. Ting Zeng per-
formed the experiments and analyzed the data. Ying Peng
r ecruitedthepa tien tsandcollectedthesam ples.
Acknowledgments
The authors gratefully acknowledge all the families who
participated in this study. This work was supported by the
ClinicalInstituteofHunanProvinceforInheritedMetabolic
disorders. This work was financially supported by Hunan
Department of Science and Technology (2014SK4044 and
2015SK2032) and National Research Program of Family
PlanningCommission(B-2015-96).
References
[1] A. Bailey, W. Phillips, and M. Rutter, â€œAutism: towards an
integration of clinical, genetic, neuropsychological, and neu-
robiological perspectives,â€ Journal of Child Psychology and
Psychiatry,vol.37 ,no .1,p p .89â€“126,1996.
[ 2 ]M .E l s a b b a g h ,G .D i v a n ,Y . - J .K o he ta l . ,â€œ G l o b a lp r e v a l e n c eo f
autism and other pervasive developmental disorders,â€Autism
Research,vol.5,no .3,p p .160â€“179 ,2012.
[3]J .H allma yer ,S.Cleveland,A.T o rr esetal.,â€œ Geneticheri tab ili ty
and shared environmental factors among twin pairs with
autism,â€ArchivesofGeneralPsychiatry ,vol.68,no.11,pp.1095â€“
1102,2011.
[4] S. M. Finegold, D. Molitoris, Y. Song et al., â€œGastrointestinal
microflora studies in late-onset autism,â€ Clinical Infectious
Diseases,vol.35,supplement1,pp.S6â€“S16,2002.
[5] Y.-J. Zhang, S. Li, R.-Y. Gan, T. Zhou, D.-P. Xu, and H.-B.
Li, â€œImpacts of gut bacteria on human health and diseases,â€
International Journal of Molecular Sciences,v o l .1 6 ,n o .4 ,p p .
7493â€“7519, 2015.
[6] Y. Song, C. Liu, and S. M. Finegold, â€œReal-time PCR quanti-
tation of clostridia in feces of autistic children,â€Applied and
Environmental Microbiology,v o l .7 0 ,n o .1 1 ,p p .6 4 5 9 â€“ 6 4 6 5 ,
2004.
[ 7 ]H .M .R .T .P a r r a c h o ,M .O .B i n g h a m ,G .R .G i b s o n ,a n dA .L .
McCartney,â€œDifferencesbetweenthegutmicrofloraofchildren
with autistic spectrum disorders and that of healthy children,â€
Journal of Medical Microbiology,v o l .5 4 ,n o .1 0 ,p p .9 8 7 â€“ 9 9 1 ,
2005.
[ 8 ]J .B .A d a m s ,L .J .J o h a n s e n ,L .D .P o w e l l ,D .Q u i g ,a n dR .
A. Rubin, â€œGastrointestinal flora and gastrointestinal status
in children with autism comparisons to typical children and
correlationwithautismseverity,â€ BMCGastroenterology,vol.11,
pp.11â€“22,2011.
[9] W. Shaw, â€œIncreased urinary excretion of a 3-(3-
hydroxyphenyl)- 3-hydroxypropionic acid (HPHPA), an
abnormal phenylalanine metabolite ofClostridia spp. in the
gastrointestinal tract, in urine samples from patients with
autism and schizophrenia,â€Nutritional Neuroscience,v o l .1 3 ,
no .3,p p .135â€“1 43,2010.
[10] L.Altieri,C.Neri,R.Saccoetal.,â€œUrinaryp-cresoliselevatedin
smallchildrenwithsevereautismspectrumdisorder , â€Biomark-
ers,vol.16,no .3,p p .25 2â€“260,2011.
[11] S. Gabriele, R. Sacco, L. Altieri et al., â€œSlow intestinal transit
contributes to elevate urinary p-cresol level in Italian autistic
children,â€Autism Research,2015.
[12] S. Gabriele, R. Sacco, S. Cerullo et al., â€œUrinary p-cresol
is elevated in young French children with autism spectrum
disorder:areplicationstudy,â€ Biomarkers,vol.19,no.6,pp.463â€“
470,2014.
[13] R.KesÂ¸li,C.G Â¨okcÂ¸en,U.Bulu Ë‡g,andY.Terzi,â€œInvestigationofthe
relationbetweenanaerobicbacteriagenusclostridiumandlate-
onset autism etiology in children,â€Journal of Immunoassay &
Immunochemistry,vol.35,no .1,p p .101 â€“109 ,201 4.
[14] L. Wang, M. A. Conlon, C. T. Christophersen, M. J. Sorich,
and M. T. Angley, â€œGastrointestinal microbiota and metabo-
lite biomarkers in children with autism spectrum disorders,â€
Biomarkers in Medicine,vol.8,no .3,p p .3 3 1 â€“344,201 4.
[ 1 5 ]X .Y .X i o n g ,X .Q .S h e n g ,D .L i u ,T .Z e n g ,Y .P e n g ,a n dY .
C. Wang, â€œA GC/MS-based metabolomic approach for reliable
diagnosis of phenylketonuria,â€ Analytical and Bioanalytical
Chemistry,vol.407 ,no .29 ,p p .8825â€“88 3 3,2015.
[16] S. M. Finegold, â€œTherapy and epidemiology of autism-
clostridial spores as key elements,â€Medical Hypotheses,v o l .7 0 ,
no .3,p p .508â€“511,2008.
[17] R. H. Sandler, S. M. Finegold, E. R. Bolte et al., â€œShort-term
benefit from oral vancomycin treatment of regressive-onset
8 BioMedResearchInternational
autism,â€Journal of Child Neurology,v o l .1 5 ,n o .7 ,p p .4 2 9 â€“ 4 3 5 ,
2000.
[18] R. Buck, J. EberspÂ¨acher, and F. Lingens, â€œDegradation and
biosynthesisofL-phenylalaninebychloridazon-degradingbac-
teria,â€Hoppe-Seylerâ€™s Zeitschrift fÂ¨ur Physiologische Chemie,v o l .
360,no.7,pp.957â€“969,1979.
[ 1 9 ]L .E .D y c k ,C .W .K a z a k o ff ,a n dC .T .D o u r i s h ,â€œ Th er o l eo f
catecholamines, 5-hydroxytryptamine and m-tyramine in the
behavioural effects of m-tyrosine in the rat,â€European Journal
of Pharmacology,vol.84,no .3-4,p p .139â€“1 49 ,1982.
[20] S. Parrott, S. Jones, and R. A. Cooper, â€œ2-Phenylethylamine
catabolism byEscherichia coliK12,â€J o u r n a lo fG e n e r a lM i c r o -
biology,vol.13 3,no .2,p p .347 â€“351,1 987 .
[21] E.DÂ´Ä±az,A.Ferr Â´andez,M.A.Prieto,andJ.L.Garc Â´Ä±a,â€œBiodegra-
dation of aromatic compounds byEscherichia coli,â€Microbiol-
ogy and Molecular Biology Reviews,v o l .6 5 ,n o .4 ,p p .5 2 3 â€“ 5 6 9 ,
2001.